Northbrook, IL 60062 -- (SBWIRE) -- 09/20/2023 -- HLA Typing Market in terms of revenue, reached an estimated value of $1.4 billion in 2022. It is now positioned for substantial growth, with projections indicating a potential value of $2.1 billion by the year 2028. This growth trajectory is characterized by a commendable compound annual growth rate (CAGR) of 6.5% anticipated from 2022 through 2028.

The driving forces behind the expansion of the neurovascular devices market are multifaceted. Primarily, it is fueled by the increasing incidence of neurovascular diseases, underpinned by factors such as improved diagnostics and awareness. Additionally, the availability of medical reimbursements for neurovascular procedures has bolstered the adoption of such treatments.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39129877

Browse in-depth TOC on "HLA Typing Market"
180 - Tables
37 - Figures
223 - Pages

Key Market Players:

Major players in neurovascular devices market include Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMérieux S.A. (France). Other players in the market are Immucor, Inc. (US), Illumina, Inc. (US), Luminex Corporation (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), GenDx (Netherlands), and Biofortuna (UK), among others.

HLA Typing Market Dynamics:

Drivers:

1. Rising number of organ transplantation procedures
2. Rising technological advancements in HLA typing
3. Increasing funding investments for research activities
4. Growing prevalence of infectious diseases

Restraints:

1. High cost of HLA typing products
2. Limited reimbursements for target procedures

Opportunities:

1. Rising adoption of cross-matching and chimerism testing procedures
2. Growing awareness of organ donations

Challenges:

1. Limited number of organ donations and long waiting lists for transplantations
2. Shortage of skilled professionals

Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=39129877

The molecular assay technologies segment accounted for the largest share of 86.5% in 2022, by technology segment.

Based on technology, the HLA typing market is segmented into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment accounted for the largest market share in 2022. The large share of the segment is attributed to the benefits of molecular assay technologies over non-molecular assays, such as low turnaround times, high procedural efficacy, multi-sample study capabilities, and real-time sample analysis.

Molecular assay techniques are used in HLA typing for applications such as donor-recipient cross-matching, cancer and autoimmune disease diagnostics, infectious disease diagnostics, and transfusion.

This market is segmented into PCR-based molecular assays and sequencing-based molecular assays. The growing demand for molecular assays is mainly attributed to their technological benefits over non-molecular assays, such as low turnaround times, high procedural efficacy, and real-time sample analysis. Other factors supporting market growth include growing applications in patient profiling, rising public-private investments for product development, and increasing evidence for the clinical efficacy of molecular assay techniques, coupled with rising technological advancements in molecular diagnostics (such as PCR and NGS).

The diagnostic applications segment is anticipated to register highest CAGR during the forecast period.

Based on application, the diagnostic applications market is segmented into Donor Recipient Cross Match, Cancer Diagnosis & Prevention, Infectious & Non-infectious disease testing, Transfusion Therapy and Others. The diagnostic applications segment accounted for the highest CAGR of 6.5% during the forecast period. The diagnostic applications segment is also projected to grow at the highest CAGR during the forecast period owing to the rising technological advancements in molecular assay techniques; increasing adoption of molecular assays for pathogen testing in infectious and non-infectious disease testing; and the growing incidence of chronic and infectious diseases.

North America to dominate the global HLA Typing Market

Based on the region, the HLA Typing Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America accounted for the largest share of neurovascular devices market. The large share of North America can be attributed to the high adoption of HLA typing devices in the region, the strong presence of companies operating in the market, and the availability of significant R&D investments for product development.

Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to the presence of a large target patient population, rising awareness on the advantages HLA typing, geographical expansion of players in region, and government initiatives to modernize & expand healthcare infrastructure.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=39129877

Recent Developments:

- In March 2023, BioRad received The company received AOAC International and AFNOR approval for its iQ-Check kits, which are used with the CFX Opus Deepwell Real-time PCR System

- In August 2022 Roche developed a new digital Light cycler system that helps determine a patient's cancer.

- In May 2022, CareDx received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT software. These AlloSeq are used in patients who have received Hematopoietic cell transplantation.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com